Medicine and Dentistry
Antibiotic Therapy
25%
Antibiotics
23%
Antifungal Agent
20%
Antifungal Therapy
25%
Bacterial Meningitis
19%
Beta Hemolytic Streptococcus
11%
Case Fatality Rate
13%
Cerebrospinal Fluid Shunting
19%
Cohort Effect
45%
COVID-19
12%
Diabetes
13%
Disease
87%
Ebolavirus
12%
Group A Streptococcal Infection
35%
Health Care
32%
Health Care Cost
14%
Health Care Provider
19%
Healthcare Associated Infection
19%
Household
10%
Hypotension
14%
Infection
88%
Infection Control
13%
Influenza Vaccination
13%
Influenza Vaccine
19%
Intensive Care Unit
12%
Meningitis
19%
Necrotizing Fasciitis
34%
Neonatal Infant
21%
Neonatal Intensive Care Unit
19%
Neonate
14%
Odds Ratio
14%
Outpatient
15%
Parenteral Drug Administration
12%
Pathogen
30%
Pediatrics
100%
Pneumococcal Infection
19%
Prematurity
11%
Primary Health Care
14%
Public Health
28%
Rabies
19%
Sepsis
12%
Septic Shock
15%
Serotype
19%
Shunt Infection
19%
Soft Tissue Infection
16%
Streptococcus Agalactiae
50%
Streptococcus Group A
16%
Systemic Candidiasis
19%
Toxic Shock Syndrome
12%
Virus Infection
14%
Pharmacology, Toxicology and Pharmaceutical Science
Amphotericin B
17%
Ampicillin
11%
Antibiotic Agent
15%
Antibiotics
15%
Antifungal Agent
9%
Antifungal Therapy
19%
Bacteremia
9%
Bacterial Meningitis
19%
Bites and Stings
9%
Bronchiolitis
11%
Bursitis
9%
Chickenpox
14%
Diarrhea
12%
Disease
53%
Envenomation
9%
Gastroenteritis
9%
Group A Streptococcal Infection
25%
Group B Streptococcal Infection
9%
Healthcare Associated Infection
9%
Human Respiratory Syncytial Virus
19%
Hypotension
11%
Infection
28%
Infectious Agent
28%
Invasive Aspergillosis
9%
Invasive Candidiasis
19%
Low Birth Weight
9%
Necrotizing Fasciitis
22%
Newborn Sepsis
9%
Palivizumab
20%
Pandemic
9%
Pertussis
9%
Placebo
14%
Pneumococcal Infection
19%
Protein Antibody
9%
Quinolone Derivative
9%
Rabies
19%
Recurrent Disease
9%
Respiratory Syncytial Virus Infection
19%
Rotavirus
19%
Salmonella
21%
Salmonellosis
28%
Short Course Therapy
9%
Staphylococcal Infection
9%
Streptococcus Agalactiae
21%
Streptococcus Group A
42%
Streptococcus Pneumoniae
11%
Syndrome
14%
Toxic Shock Syndrome
20%
Urinary Tract Infection
9%
Vaccination Policy
26%
Keyphrases
American Academy of Pediatrics
12%
Amphotericin B
14%
Calgary
15%
Canada
32%
Canadian Perspective
9%
Capsular Genes
9%
Childhood Fever
9%
Combination Antifungal Therapy
9%
Community-acquired Pneumonia in children
9%
Core Genome multilocus Sequence Typing (cgMLST)
13%
CSF Shunt Infection
9%
Dean's Office
9%
Draft Genome Sequence
9%
Economic Evaluation
9%
Environmental Risk
9%
Extended Reality
9%
Genetic Diversity
11%
Genital Infection
9%
Group B Streptococcus
16%
Healthcare-associated Infections
9%
Hospitalization Rate
9%
Hospitalization Risk
19%
Hypotension
12%
Immunocompromised Pediatric Patients
9%
Infectious Disease Specialist
12%
Influenza Immunization
14%
Late-onset Sepsis
9%
Michigan
28%
Microbiological Treatment
9%
Non-typhoidal Salmonella
19%
Office Setting
9%
Palivizumab
16%
Palivizumab Prophylaxis
19%
Pediatric
19%
Pharyngitis
9%
Pregnant Women
13%
Reimplantation
9%
Respiratory Syncytial Virus Hospitalization
10%
Risk Factors
12%
Rotavirus Gastroenteritis
9%
Salmonella Infection
25%
Salmonellosis
9%
Severe Group
12%
Should Be Given
9%
Sports Control
9%
Study of Disease
9%
Treatment Failure
9%
University Departments
9%
Virus Detection
9%
Young children
13%
